Drug intelligence / Profile preview

niraparib + pembrolizumab

Development stage: Unknown
Lead developer: GSK
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
Administration: Oral, Intravenous

Overview

Niraparib + pembrolizumab is a combination therapy that pairs a poly(ADP-ribose) polymerase (PARP) inhibitor (niraparib) with a programmed cell death receptor-1 (PD-1) inhibitor (pembrolizumab). This combination is designed to potentially create synergy between PARP inhibition and immune checkpoint blockade, enhancing both adaptive and innate antitumor immune responses. The combination has shown promising antitumor activity in clinical trials for various cancer types, including ovarian carcinoma, triple-negative breast cancer, and non-small cell lung cancer.

Targets

PDCD1 (Programmed cell death protein 1 receptor)PARP2 (Poly (adp-ribose) polymerase 2)

Beyond the preview

Go deeper on niraparib + pembrolizumab.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on niraparib + pembrolizumab.

Explore the full profile